Compare Charles River Laboratories Intl. Inc (CRL) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VICI Properties Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.54 (market cap $11.14B), while VICI Properties Inc trades at $26.51 (market cap $28.94B). The key difference: VICI Properties Inc is far larger — about 2.6× Charles River Laboratories Intl. Inc's market cap, and VICI Properties Inc pays a 6.85% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | VICI | |
|---|---|---|
Market Cap | $11.14B | $28.94B |
Sector | Health | Real Estate |
52-Week High | $233.60 | $33.93 |
52-Week Low | $145.57 | $25.94 |
Enterprise Value | $14.00B | $46.16B |
Dividend Yield | — | 6.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VICI Properties trades at $26.40, up 1.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The REIT shows strong fundamentals with a P/E of 9, net income margin of 76.83%, and consistent cash flow generation. Recent news highlights its 6.8% dividend yield and investment-grade balance sheet, though concerns linger over tenant concentration with Caesars and MGM accounting for 70% of rent.
The outlook remains positive with a consensus price target of $30.75 implying 16.5% upside, supported by 20 buy ratings. Risks include Las Vegas market exposure and potential lease uncertainties from tenant buyouts, but the stock's discounted valuation and secure dividend profile offer a compelling case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
